History

1. 2025

   1. Adrixetinib (Q702), completion of US FDA Phase 1 study and receipt of Clinical Study Report (CSR)

      12.29

   2. Capital raise of 10.7 billion KRW in QLi5 Therapeutics AG (Subsidiary)

      12.22

   3. Adrixetinib (Q702) monotherapy, Spain approval for Phase 1b study in chronic graft-versus-host disease (cGvHD)

      11.25

   4. Capital raise of 9 billion KRW through BW and 12.8 billion KRW through CB

      11.06

   5. Platform technology in-licensing agreement with Synaffix B.V. for the development of dual-payload ADCs

      09.25

   6. Adrixetinib cGvHD clinical study selected for support under the Korea Drug Development Fund (KDDF) national new drug development program

      06.20

   7. Capital raise of 8 billion KRW

      04.10

   8. Telacebec (Q203), interim results of the Australian clinical study presented at the WHO global meeting

      03.26

   9. Adrixetinib (Q702) monotherapy, US FDA IND approval for Phase 1b study in chronic graft-versus-host disease (cGvHD)

      01.02

2. 2024

   1. Awarded the Minister of Health and Welfare Commendation for contribution as a Korea Innovative Pharmaceutical Company

      11.28

   2. Capital raise of 6 billion KRW through perpetual convertible bond

      11.22

   3. Capital raise of 8 billion KRW

      07.29

   4. Adrixetinib (Q702) in triple combination with Aza-Ven (azacitidine, venetoclax), US FDA IND approval for investigator-initiated Phase 1 study in acute myeloid leukemia (AML)

      06.19

   5. Adrixetinib (Q702) monotherapy, US FDA IND approval for investigator-initiated Phase 1/2 study in histiocytic neoplasms

      06.14

   6. Telacebec (Q203), initiation of the registrational clinical study in Australia

      05.23

   7. Cooperative Research and Development Agreement (CRADA) signed with the US National Cancer Institute (NCI) for Q901 in combination with ADCs

      05.21

   8. Capital raise of 13.5 billion KRW and change of largest shareholder (Institut Pasteur Korea → Dongkoo Bio & Pharma Co., Ltd.)

      05.17

3. 2023

   1. Capital raise of 2.5 billion KRW

      12.27

   2. Capital raise of 3.5 billion KRW through perpetual convertible bond

      12.27

   3. Capital raise of 25.2 billion KRW

      12.15

   4. Cooperative research and development agreement signed with the US National Cancer Institute (NCI) for Q901

      08.12

   5. MFDS approval for Q901 Phase 1/2 study

      06.21

   6. MFDS IND filing for Q901 Phase 1/2 study

      04.03

   7. Exclusive License Agreement with TB Alliance to develop and commercialize Telacebec(Q203)

      02.03

   8. Designated as “Korea Innovative Pharmaceutical Company” (Ministry of Health and Welfare)

      01.19

4. 2022

   1. Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA®

      09.14

   2. MFDS approval for Q702 phase 1b/2 study in Combination With KEYTRUDA®

      09.06

   3. US FDA IND filing for Q702 phase 1b/2 study in Combination With KEYTRUDA®

      02.16

   4. Telacebec(Q203), voluntarily suspend of COVID-19 phase 2 study in public of South Africa

      02.11

   5. Q901, US FDA approval for phase 1/2 study

      02.08

5. 2021

   1. Capital raise of 5 million EUR in QLi5 Therapeutics(Subsidiary)

      12.22

   2. Capital raise of 12.5 billion KRW

      12.17

   3. Collaboration Agreement with MSD to Evaluate Selective Triple Inhibitor Q702 in Combination With KEYTRUDA®

      11.23

   4. Q702, Presented by SWOG(Southwest Oncology Group) Fall 2021 Meeting

      10.14

   5. Posted 2021 AACR annual meeting(Q901)

      04.12

   6. Q702, Initiation of clinical patient dosing for phase 1/2 study in US

      01.26

   7. FDA grants orphan drug designation to Qurient’s Buruli ulcer treatment(Telacebec)

      01.14

6. 2020

   1. Telacebec(Q203), approval for COVID-19 phase 2 study in Republic of South Africa

      11.24

   2. Capital raise of 60 billion KRW

      10.29

   3. Telacebec(Q203), IND filing of COVID-19 phase 2 study in Republic of South Africa

      10.13

   4. Telacebec(Q203), Signed a Material Transfer Agreement with Janssen

      09.24

   5. Posted 2020 AACR annual meeting (Q702 / Q901)

      06.23

   6. Q301, Completion of phase 2b study

      05.28

   7. Q702, US FDA approval for Immuno-oncology therapy phase 1 study

      05.23

   8. Published in New England Journal of Medicine(NEJM) to result of Telacebec(Q203) phase 2a study

      03.26

   9. Establishment of subsidiary "QLi5 Therapeutics GmbH" in Germany

      01.16

7. 2019

   1. Telacebec(Q203), Completion of Tuberculosis phase 2a study

      12.17

   2. Posted 2019 AACR annual meeting in Atlanta (Q702)

      04.02

   3. Q301 Phase 2a Results presented at 2019 American Academy of Dermatology Annual Meeting in Washington DC

      03.02

8. 2018

   1. Telacebec (Q203) U.S. FDA Fast Track Designation

      11.12

   2. Capital raise of 40 billion KRW

      10.19

   3. Received grant from Korea Drug Development Fund for Telacebec (Q203) Phase 2a study

      10.01

   4. US FDA approval for Telacebec (Q203) phase 2a study

      07.16

   5. US FDA approval for Q301 phase 2b study

      06.21

   6. Completion of TB Telacebec (Q203) phase 1b study

      05.05

   7. Confirmation of “Telacebec ” as a generic name for Q203 by INN & USAN

      03.01

9. 2017

   1. South Africa MCC approval for Q203 phase 2a study

      12.20

   2. Posted 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Q701 & Q702 / Q901 )

      10.26

   3. Published in European Journal of Medicinal Chemistry. 136 (2017);420-427 (Title : Synthesis and structure-activity relationships of novel fused ring analogues of Q203 as antitubercular agents)

      08.18

   4. EDCTP(European & Developing Countries Clinical Trials Partnership) grant awarded to PanACEA consortium to run Q203 clinical studies

      02.28

   5. Published in European Journal of Medicinal Chemistry. 125 (2017);807-815 (Title : Synthesis and structure-activity studies of side chain analogues of the anti-tubercular agent, Q203)

      01.05

10. 2016

    1. US FDA approval for Q203 Phase 1b study

       08.29

    2. Completion of Q301 phase 2a study

       05.19

    3. Initial public offering on Korea Exchange (KRX:115180)

       02.29

11. 2015

    1. Q203 U.S. FDA Orphan Drug Designation

       12.28

    2. Received grant from Korea Drug Development Fund for Q203 phase 1 study

       12.16

    3. US FDA IND approval for Q203 phase 1 study

       07.23

    4. US FDA approval for Q301 phase 2a study

       03.12

    5. In-licensed CDK7 inhibitor program from Max Planck Innovation / Lead Discovery Center

       02.27

    6. Umbrella partnership agreement signed with Max Planck Innovation / Lead Discovery Center

       02.06

12. 2014

    1. Capital raise of 15.5 billion KRW

       06.09

    2. Published in Journal of Medicinal Chemistry. 57(12);5293–5305 (Title : Lead Optimization of a Novel Series of Imidazo[1,2-a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent)

       05.28

    3. Russia and CIS rights for Q203 licensed to Infectex (a subsidiary company of Maxwell Biotech Group, Russia)

       01.21

13. 2013

    1. Published in Nature medicine. 19(9);1157-60. (Title : Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis)

       08.04

    2. Capital raise of 3 billion KRW

       05.10

    3. Received grant from Korea Drug Development Fund for Q203 preclinical IND enabling studies

       04.30

    4. In-licensed Axl inhibitor program from Max Planck Innovation / Lead Discovery Center

       02.21

14. 2012

    1. Capital raise of 3 billion KRW

       09.19

15. 2011

    1. Company name change to “Qurient Co., Ltd”

       10.21

    2. Capital raise of 1 million USD

       02.09

16. 2010

    1. Won Gate II competition for 1M USD investment by Novartis Venture Fund

       09.02

    2. In-licensed anti-tuberculosis antibiotics programs from Institut Pasteur Korea

       03.04

17. 2009

    1. Series A finance of 4 billion KRW

       11.20

18. 2008

    1. Foundation of Qurient (formerly Quro Science Co. Ltd.)

       07.02